IP Library Granted Patent US 10,588,858
Granted Patent B2
US 10,588,858 · App. 16/443,649 · Granted Mar 17, 2020

Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof

Inventors: Dov Tamarkin (Ness Ziona, IL); David Schuz (Gimzu, IL); Tal Berman (Rishon le Ziyyon, IL); Yohan Hazot (Rehovot, IL)
Assignee: FOAMIX PHARMACEUTICALS LTD.
A61K9/122A61K8/046A61K8/46A61K9/0014A61K47/14A61K47/20A61K47/26A61K47/38A61Q19/00A61K2800/31
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,588,858
App. No.
16/443,649
Granted
Mar 17, 2020
Kind
B2
Abstract

The present invention teaches a foamable pharmaceutical and cosmetic compositions comprising an aprotic polar solvent; foam compositions and uses thereof.

Claims (25)

1. A foam able composition formulated for administration to the skin comprising a carrier composition comprising:

a) a short chain alcohol comprising ethanol present at a concentration of at least 55% by weight of the carrier;

b) about 2% to about 50% by weight of the carrier of a protic polar solvent comprising propylene glycol;

c) a polymeric agent comprising a cellulose ether, wherein the cellulose ether is a hydroxypropyl cellulose present at a concentration of about 0.5% to about 1% by weight of the carrier;

d) a modulating agent comprising an antioxidizing agent present at a concentration of about 0.1% to about 10% by weight of the carrier;

e) a metal;

f) an essential oil; and

g) tetracycline in a therapeutically effective amount of about 1% to about 5% by weight of the carrier,

wherein the composition is surfactant free, nonaqueous, and tree or essentially free of fatty alcohol.

2. The foamable composition of claim 1 , wherein the protic polar solvent is at a concentration of about 12% to about 30% by weight of the carrier.

3. The foamable composition of claim 1 , further comprising a liquefied or compressed gas propellant present at a concentration of about 3% to about 25% by weight of the foamable composition.

4. A foamable composition formulated for administration to the skin comprising a carrier composition comprising:

a) a short chain alcohol comprising ethanol;

b) about 12% to about 30% by weight of the carrier of a protic polar solvent comprising propylene glycol;

c) a polymeric agent comprising a cellulose ether;

d) a modulating agent comprising an antioxidizing agent;

e) a metal;

f) an essential oil; and

g) tetracycline in a therapeutically effective amount of about 1% to about 5% by weight of the carrier,

wherein the composition is surfactant free, nonaqueous, and free or essentially free of fatty alcohol.

5. The foamable composition of claim 4 , wherein the short chain alcohol is present at a concentration of at least 55% by weight of the carrier.

6. The foamable composition of claim 4 , wherein the cellulose ether is a hydroxypropyl cellulose.

7. The foamable composition of claim 4 , wherein the cellulose ether is present in a concentration of about 0.5% to about 1% by weight of the carrier.

8. The foamable composition of claim 4 , wherein the modulating agent is present at a concentration of about 0.1% to about 10% by weight of the carrier.

9. The foamable composition of claim 4 , further comprising a liquefied or compressed propellant at a concentration of about 3% to about 25% by weight of the foamable composition.

Assignments (11)
SECURITY INTEREST Recorded Dec 28, 2023
From: JOURNEY MEDICAL CORPORATION; JG PHARMA, INC.
To: SWK FUNDING LLC
Reel/Frame 066157/0079 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2022
From: VYNE THERAPEUTICS INC.; VYNE PHARMACEUTICALS INC.
To: JOURNEY MEDICAL CORPORATION
Reel/Frame 058925/0568 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2021
From: VYNE THERAPEUTICS INC.
To: VYNE PHARMACEUTICALS INC.
Reel/Frame 058463/0167 →
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2021
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: VYNE PHARMACEUTICALS LTD. (F/K/A FOAMIX PHARMACEUTICALS LTD.)
Reel/Frame 057544/0138 →
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2021
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.)
Reel/Frame 057544/0708 →
PATENT SECURITY AGREEMENT Recorded Feb 17, 2021
From: VYNE THERAPEUTICS INC.
To: PERCEPTIVE CREDIT HOLDINGS II, LP
Reel/Frame 055326/0009 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2021
From: VYNE PHARMACEUTICALS LTD.
To: VYNE THERAPEUTICS INC.
Reel/Frame 055215/0298 →
CHANGE OF NAME Recorded Nov 4, 2020
From: FOAMIX PHARMACEUTICALS LTD.
To: VYNE PHARMACEUTICALS LTD.
Reel/Frame 054306/0387 →
PATENT SECURITY AGREEMENT Recorded Jul 30, 2019
From: FOAMIX PHARMACEUTICALS LTD
To: PERCEPTIVE CREDIT HOLDINGS II, LP
Reel/Frame 049912/0045 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 17, 2019
From: TAMARKIN, DOV; SCHUZ, DAVID; BERMAN, TAL; HAZOT, YOHAN
To: FOAMIX LTD.
Reel/Frame 049493/0081 →
CHANGE OF NAME Recorded Jun 17, 2019
From: FOAMIX LTD.
To: FOAMIX PHARMACEUTICALS, LTD.
Reel/Frame 049494/0713 →
Continuity (6)
Continuation 16236704 · Dec 31, 2018
Continuation 15883134 · Jan 30, 2018
Continuation 15639114 · Jun 30, 2017
Division 13263201
Provisional Application 61173378 · Apr 28, 2009
Related Publication 20200016077A1 · Jan 16, 2020
Cited By (1)
US 12,661,407